123 related articles for article (PubMed ID: 22180717)
1. Neuroendocrine and squamous colonic composite carcinoma: case report with molecular analysis.
Wentz SC; Vnencak-Jones C; Chopp WV
World J Gastroenterol; 2011 Nov; 17(42):4729-33. PubMed ID: 22180717
[TBL] [Abstract][Full Text] [Related]
2. Coexisting tubular adenoma with a neuroendocrine carcinoma of colon allowing early surgical intervention and implicating a shared stem cell origin.
Soliman ML; Tiwari A; Zhao Q
World J Gastroenterol; 2017 Feb; 23(6):1106-1112. PubMed ID: 28246485
[TBL] [Abstract][Full Text] [Related]
3. [Comparative analysis of real-time quantitative PCR-Sanger sequencing method and TaqMan probe method for detection of KRAS/BRAF mutation in colorectal carcinomas].
Zhang X; Wang Y; Gao N; Wang J
Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):77-82. PubMed ID: 24742565
[TBL] [Abstract][Full Text] [Related]
4. Colorectal neuroendocrine carcinomas and adenocarcinomas share oncogenic pathways. A clinico-pathologic study of 12 cases.
Karkouche R; Bachet JB; Sandrini J; Mitry E; Penna C; Côté JF; Blons H; Penault-Llorca F; Rougier P; Saint André JP; Emile JF
Eur J Gastroenterol Hepatol; 2012 Dec; 24(12):1430-7. PubMed ID: 23114745
[TBL] [Abstract][Full Text] [Related]
5. Mixed large cell neuroendocrine carcinoma and squamous cell carcinoma of the colon: detailed molecular characterisation of two cases indicates a distinct colorectal cancer entity.
Woischke C; Jung P; Jung A; Kumbrink J; Eisenlohr S; Auernhammer CJ; Vieth M; Kirchner T; Neumann J
J Pathol Clin Res; 2021 Jan; 7(1):75-85. PubMed ID: 33197299
[TBL] [Abstract][Full Text] [Related]
6. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
[TBL] [Abstract][Full Text] [Related]
7. Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability.
Umeda Y; Nagasaka T; Mori Y; Sadamori H; Sun DS; Shinoura S; Yoshida R; Satoh D; Nobuoka D; Utsumi M; Yoshida K; Yagi T; Fujiwara T
J Hepatobiliary Pancreat Sci; 2013 Feb; 20(2):223-33. PubMed ID: 23010994
[TBL] [Abstract][Full Text] [Related]
8. BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features.
Pai RK; Jayachandran P; Koong AC; Chang DT; Kwok S; Ma L; Arber DA; Balise RR; Tubbs RR; Shadrach B; Pai RK
Am J Surg Pathol; 2012 May; 36(5):744-52. PubMed ID: 22314188
[TBL] [Abstract][Full Text] [Related]
9. Colorectal poorly differentiated neuroendocrine carcinomas frequently exhibit BRAF mutations and are associated with poor overall survival.
Olevian DC; Nikiforova MN; Chiosea S; Sun W; Bahary N; Kuan SF; Pai RK
Hum Pathol; 2016 Mar; 49():124-34. PubMed ID: 26826419
[TBL] [Abstract][Full Text] [Related]
10. Influence of anatomical subsite on the incidence of microsatellite instability, and KRAS and BRAF mutation rates in patients with colon carcinoma.
Benedix F; Meyer F; Kube R; Kropf S; Kuester D; Lippert H; Roessner A; Krüger S
Pathol Res Pract; 2012 Oct; 208(10):592-7. PubMed ID: 22898351
[TBL] [Abstract][Full Text] [Related]
11. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.
Roth AD; Tejpar S; Delorenzi M; Yan P; Fiocca R; Klingbiel D; Dietrich D; Biesmans B; Bodoky G; Barone C; Aranda E; Nordlinger B; Cisar L; Labianca R; Cunningham D; Van Cutsem E; Bosman F
J Clin Oncol; 2010 Jan; 28(3):466-74. PubMed ID: 20008640
[TBL] [Abstract][Full Text] [Related]
12. KRAS and BRAF mutation analysis in routine molecular diagnostics: comparison of three testing methods on formalin-fixed, paraffin-embedded tumor-derived DNA.
Heideman DA; Lurkin I; Doeleman M; Smit EF; Verheul HM; Meijer GA; Snijders PJ; Thunnissen E; Zwarthoff EC
J Mol Diagn; 2012; 14(3):247-55. PubMed ID: 22425762
[TBL] [Abstract][Full Text] [Related]
13. Prognostic relevance of occult metastases detected by cytokeratin 20 and mucin 2 mRNA levels in sentinel lymph nodes from colon cancer patients.
Nordgård O; Oltedal S; Aasprong OG; Søreide JA; Søreide K; Tjensvoll K; Gilje B; Heikkilä R; Guriby M; Lothe RA; Smaaland R; Kørner H
Ann Surg Oncol; 2012 Nov; 19(12):3719-26. PubMed ID: 22752373
[TBL] [Abstract][Full Text] [Related]
14. Molecular and immunohistochemical profile of a basaloid (cloacogenic) carcinoma of the sigmoid colon: possible predictive value for clinical outcomes.
Gurzu S; Szentirmay Z; Bara T; Bara T; Iurcsuk O; Jung I
Eur J Gastroenterol Hepatol; 2014 May; 26(5):570-3. PubMed ID: 24584270
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis.
Zlobec I; Bihl MP; Schwarb H; Terracciano L; Lugli A
Int J Cancer; 2010 Jul; 127(2):367-80. PubMed ID: 19908233
[TBL] [Abstract][Full Text] [Related]
16. Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency.
Dawson H; Galván JA; Helbling M; Muller DE; Karamitopoulou E; Koelzer VH; Economou M; Hammer C; Lugli A; Zlobec I
Int J Cancer; 2014 May; 134(10):2342-51. PubMed ID: 24166180
[TBL] [Abstract][Full Text] [Related]
17. BRAF-mutated microsatellite stable colorectal carcinoma: an aggressive adenocarcinoma with reduced CDX2 and increased cytokeratin 7 immunohistochemical expression.
Landau MS; Kuan SF; Chiosea S; Pai RK
Hum Pathol; 2014 Aug; 45(8):1704-12. PubMed ID: 24908142
[TBL] [Abstract][Full Text] [Related]
18. Role of oncogenic pathways and KRAS/BRAF mutations in the behavior of colon adenocarcinoma in renal transplant patients.
Revuelta I; Moya-Rull D; García-Herrera A; Rovira J; Ayala de la Peña F; Misiego A; Guzmán F; Oppenheimer F; Albanell J; Campistol JM
Transplantation; 2012 Mar; 93(5):509-17. PubMed ID: 22245873
[TBL] [Abstract][Full Text] [Related]
19. KRAS mutations in traditional serrated adenomas from Korea herald an aggressive phenotype.
Kim KM; Lee EJ; Kim YH; Chang DK; Odze RD
Am J Surg Pathol; 2010 May; 34(5):667-75. PubMed ID: 20305537
[TBL] [Abstract][Full Text] [Related]
20. Expression of Abelson interactor 1 (Abi1) correlates with inflammation, KRAS mutation and adenomatous change during colonic carcinogenesis.
Steinestel K; Brüderlein S; Steinestel J; Märkl B; Schwerer MJ; Arndt A; Kraft K; Pröpper C; Möller P
PLoS One; 2012; 7(7):e40671. PubMed ID: 22808230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
